The Relationship Between HBV Genotype And The Virology Response Of Lamivudine

Objective :To evaluate the relationship between HBV genotypes and the antiviral response of lamivudine treatment in chronic patients with infecting HBV. Methods: Clinical data was collected by prospective method linked retrospective method. Fifty-three patients with infecting HBV received lamivudine 100 mg/day, oral application for at least 12 months and observed regularly until 6 months after drug withdrawal. HBV genotype was determined by the nested PCR with multiple x pairs of primers and mutations in the pre-core (PC) and basic core promoter (BCP) region was detected by PCR-gene sequence analysis while HBVDNA rebound after therapy. Results: The most frequent genotype were C (45.3%), 2 patients were mixed genotypes while 41.5% had genotype B. Genotype A,D, E and F was not found. The sex, age, ALT and HBVDNA level was not significant deviation between the patients of genotype B and C, and the virology respond was not significant deviation between them at time of 6 months, 12 months and the time of drug withdrawal. It was significant deviation at 6 months after drug withdrawal. The two genotypes have not obvious difference of the pre-core mutation, but have obvious difference of the basal core promoter region mutation. The mutation of BCP in the patients of genotype C is significantly more frequent than genotype B. Conclusion: The virology respond of lamivudine is not related with the sex, age, genotype, time of therapy, the level of ALT and HBVDNA of the patients who have treated for at least one year. However, HBV genotype and the level of ALT and HBVDNA is associated with the virology respond of lamivudine after 6 month of drug withdrawal. Genotype B outweigh genotype C. Genotype C is more frequently generate BCP mutation than genotype B. HBV genotypes may be an important determinant of antiviral therapy of chronic patients with infecting HBV as well as the level of ALT and HBVDNA.